Login to Your Account

Cethromycin in the Antibiotic Queue

Advanced Life Sciences Submits NDA; Secures Partner, Financing

By Jennifer Boggs

Thursday, October 2, 2008
Advanced Life Sciences Holdings Inc. had Wednesday what Chairman and CEO Michael Flavin called "a great day," with the submission of its regulatory application for antibiotic cethromycin in community-acquired pneumonia (CAP), a potential $100 million-plus Asia-Pacific partnership deal with Wyeth and a couple of financing agreements to bolster its cash position. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription